LAUSR

Postoperative chemoradiotherapy (CRT), using conventional radiotherapy (convRT), has a key role in the treatment of glioblastoma (GBM) supported by level 1A evidence. In the past decade, evidence supporting hypofractionated radiotherapy (HFRT) has emerged. However, GBM patients in clinical trials are highly selected. Consequently, real-world patients may not be able to undergo evidence-based treatments. The aim of this retrospective Danish cohort study was to evaluate the utilisation of and compliance with postoperative CRT in real-world GBM patients over time. All adults (≥18 years) with newly diagnosed GBM (histology confirmed) between 2011 and 2018 were identified via the Danish Neuro-Oncology Registry, which was furthermore used to extract all data. Radiotherapy (RT) was classified as convRT (≤2 Gy/fr, planned dose 44–66 Gy) or HFRT (>2 Gy/fr, planned dose 34 or 40 Gy). The utilisation of and compliance with CRT (only concomitant treatment assessed) was measured by intended and administered treatment, respectively. To assess trends, patients were grouped per year of diagnosis. Multivariable logistic regression was used to analyse the association of age (